Department of Maternal and Child Health and Urological Sciences, Umberto I Polyclinic Hospital, Sapienza University, Rome, Italy -
Department of Maternal and Child Health and Urological Sciences, Umberto I Polyclinic Hospital, Sapienza University, Rome, Italy.
Minerva Ginecol. 2020 Oct;72(5):339-348. doi: 10.23736/S0026-4784.20.04624-9. Epub 2020 Aug 3.
BRCA1 and BRCA2 genes mutations seems to impact female fertility, in addition to increasing the risk of ovarian and breast cancer. Several studies had investigated this issue but data available are still controversial. In order to clarify the role of BRCA1 and BRCA2 mutations in female fertility and ovarian function we carried out a systematic review of the literature with the aim to establish a possible management's strategy of these patients.
A review of current literature regarding BRCA mutation (BRCAm) and fertility was conducted using the PubMed tool to select remarkable articles with the keywords "BRCA1/2 gene," "BRCA1/2 mutation," "anti-Müllerian hormone," "female fertility," "ovarian reserve" and "premature ovarian failure."
In current literature there are controversial findings about the relation between BRCA genes mutations and lifespan of female reproductive age. Several studies showed an higher risk of premature ovarian insufficiency of BRCAs mutations carriers, according to lower serum AMH level, primordial follicle count, or fewer oocyte yield after ovarian stimulation; on the other hand more recent studies reported not significant differences in serum AMH level or in reproductive outcomes between mutated and non-mutated BRCA patients. For this reason, currently there is not a strict recommendation for routine evaluation of fertility in female carriers of BRCA mutations. Nevertheless, the strong advice to complete childbearing by age 40 and then to undergo a risk-reducing salpingo-oophorectomy and the increased risk of infertility as a result of anticancer treatment in breast cancer BRCAm patients, make the issue of fertility and pregnancy planning in these women worthy of consideration.
A dedicated counseling to discuss these issues, eventually associated with a personalized assessment of serum AMH or antral follicle count in order to have a panoramic view of ovarian reserve, may be useful in the management of these patients.
BRCA1 和 BRCA2 基因突变似乎除了增加卵巢癌和乳腺癌的风险外,还会影响女性的生育能力。已经有几项研究调查了这个问题,但现有的数据仍存在争议。为了阐明 BRCA1 和 BRCA2 突变对女性生育能力和卵巢功能的影响,我们对文献进行了系统回顾,旨在为这些患者制定可能的管理策略。
使用 PubMed 工具回顾了当前关于 BRCA 突变(BRCAm)和生育能力的文献,使用关键词“BRCA1/2 基因”、“BRCA1/2 突变”、“抗苗勒管激素”、“女性生育能力”、“卵巢储备”和“卵巢早衰”选择了有意义的文章。
目前的文献中,BRCA 基因突变与女性生殖年龄寿命之间的关系存在争议。一些研究表明,BRCA 基因突变携带者发生卵巢早衰的风险更高,这与血清 AMH 水平较低、原始卵泡计数较少或卵巢刺激后获得的卵母细胞数量较少有关;另一方面,最近的研究报告称,BRCA 基因突变和非突变患者的血清 AMH 水平或生殖结局无显著差异。因此,目前对于 BRCA 基因突变女性携带者是否需要常规进行生育能力评估尚无明确建议。然而,强烈建议 BRCA 基因突变携带者在 40 岁之前完成生育,然后进行降低风险的输卵管卵巢切除术,以及乳腺癌 BRCAm 患者因抗癌治疗而导致的不孕风险增加,使得这些女性的生育和妊娠计划问题值得考虑。
进行专门的咨询以讨论这些问题,最终结合血清 AMH 或窦卵泡计数的个性化评估,以全面了解卵巢储备情况,可能有助于这些患者的管理。